Teduglutide
Teduglutide is an FDA-approved GLP-2 analog. Teduglutide differs from native GLP-2 by a single alanine-to-glycine substitution at position 2, which prevents cleavage by dipeptidyl peptidase-4 and extends its half-life substantially. Acting through the GLP-2 receptor on intestinal subepithelial myofibroblasts and enteric neurons, it promotes mucosal growth, increases villus height and crypt depth, and improves intestinal fluid and nutrient absorption.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 3752.1 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Recombinant analog of glucagon-like peptide-2 approved for adults and children with short bowel syndrome who depend on parenteral support. It is the only approved peptide acting specifically on intestinal mucosal growth.
Peptide Library's Teduglutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Teduglutide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Amino acid sequence | His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp |
|---|---|
| Molecular formula | C164H252N44O55S |
| Molecular weight | 3752.1 g/mol |
| PubChem CID | 16139605 |
| FDA UNII | 7M19191IKG |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Teduglutide differs from native GLP-2 by a single alanine-to-glycine substitution at position 2, which prevents cleavage by dipeptidyl peptidase-4 and extends its half-life substantially. Acting through the GLP-2 receptor on intestinal subepithelial myofibroblasts and enteric neurons, it promotes mucosal growth, increases villus height and crypt depth, and improves intestinal fluid and nutrient absorption.
Studies
- [Review of real-life teduglutide experience]
- Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support
- Teduglutide for pediatric short bowel syndrome patients
- Teduglutide for the treatment of short bowel syndrome - a safety evaluation
- Teduglutide for treatment of adult patients with short bowel syndrome
Regulatory & research status
Teduglutide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Teduglutide: frequently asked questions
What is Teduglutide?
Recombinant analog of glucagon-like peptide-2 approved for adults and children with short bowel syndrome who depend on parenteral support. It is the only approved peptide acting specifically on intestinal mucosal growth.
How does Teduglutide work?
Teduglutide differs from native GLP-2 by a single alanine-to-glycine substitution at position 2, which prevents cleavage by dipeptidyl peptidase-4 and extends its half-life substantially. Acting through the GLP-2 receptor on intestinal subepithelial myofibroblasts and enteric neurons, it promotes mucosal growth, increases villus height and crypt depth, and improves intestinal fluid and nutrient absorption.
Is Teduglutide FDA approved?
Yes. Teduglutide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the amino acid sequence of Teduglutide?
Teduglutide has the sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp, giving a chain of 33 amino acids. Its molecular formula is C164H252N44O55S.
What peptides are similar to Teduglutide?
Compounds most often compared with Teduglutide include Linaclotide, Plecanatide, Larazotide and Secretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Review of real-life teduglutide experience] — Nutr Hosp, 2023External reference
- Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support — J Pediatr Gastroenterol Nutr, 2023External reference
- Teduglutide for pediatric short bowel syndrome patients — Expert Rev Gastroenterol Hepatol, 2021External reference
- Teduglutide for the treatment of short bowel syndrome - a safety evaluation — Expert Opin Drug Saf, 2018External reference
- Teduglutide for treatment of adult patients with short bowel syndrome — Expert Opin Biol Ther, 2017External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Teduglutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Teduglutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →